Research analysts at Barclays started coverage on shares of Mediclinic International (LON:MDC) in a research report issued on Friday. The firm set an “overweight” rating and a GBX 751 ($10.55) price target on the stock. Barclays’ price objective would suggest a potential upside of 28.24% from the company’s previous close.
Several other research analysts also recently commented on the company. Credit Suisse Group lifted their target price on Mediclinic International from GBX 265 ($3.72) to GBX 305 ($4.28) and gave the stock a “neutral” rating in a report on Thursday, October 26th. Jefferies Group raised Mediclinic International to a “buy” rating and lifted their target price for the stock from GBX 550 ($7.72) to GBX 616 ($8.65) in a report on Thursday, November 30th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a GBX 695 ($9.76) target price on shares of Mediclinic International in a report on Tuesday, December 12th. Citigroup reaffirmed a “neutral” rating on shares of Mediclinic International in a report on Tuesday, November 21st. Finally, Macquarie cut their target price on Mediclinic International from GBX 760 ($10.67) to GBX 660 ($9.27) and set a “neutral” rating on the stock in a report on Friday, October 20th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the stock. Mediclinic International has an average rating of “Hold” and an average target price of GBX 693.20 ($9.73).
Shares of Mediclinic International (LON MDC) traded down GBX 6.40 ($0.09) on Friday, reaching GBX 585.60 ($8.22). The company’s stock had a trading volume of 2,446,304 shares, compared to its average volume of 1,200,000. The firm has a market cap of $4,320.00 and a P/E ratio of 6,506.67. Mediclinic International has a 52-week low of GBX 495.40 ($6.96) and a 52-week high of GBX 890.18 ($12.50).
COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/03/barclays-begins-coverage-on-mediclinic-international-mdc.html.
Mediclinic International plc is an international private healthcare provider. The Company’s segments include Mediclinic Southern Africa, Mediclinic Switzerland, Mediclinic Middle East, United Kingdom and Corporate. It focuses on providing acute care and multidisciplinary healthcare services. It has interest in Spire Healthcare, a United Kingdom-based private healthcare company.
Receive News & Ratings for Mediclinic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediclinic International and related companies with MarketBeat.com's FREE daily email newsletter.